Mazdutide (TFA)

• Description :

  Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR) . Mazdutide TFA binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM) . Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) [1][2][3].

• Product Name Alternative :

  IBI-362 (TFA) ; LY-3305677 (TFA) ; OXM-3 (TFA)

• UNSPSC :

  12352209

• Target :

  GCGR; GLP Receptor

• Type :

  Peptides

• Related Pathways :

  GPCR/G Protein

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/mazdutide-tfa.html

• Purity :

  99.67

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  [Mazdutide(TFA)]

• Molecular Formula :

  C210H322N46O67.xC2HF3O2

• Molecular Weight :

  4563.06 (free base)

• References & Citations :

  [1]Chen T, et al. The Design and Optimization of Monomeric Multitarget Peptides for the Treatment of Multifactorial Diseases. J Med Chem. 2022 Mar 10;65 (5) :3685-3705.|[2]Jiang H, et al. A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nat Commun. 2022 Jun 24;13 (1) :3613.|[3]Chen Y, Mezo A, Coskun T, et al. 682-P: novel dual glucagon and glucagon-like peptide-1 receptor agonist LY3305677 improves glucose control, reduces body weight, and increases energy expenditure in mice[J]. Diabetes, 2021, 70 (Supplement_1) .

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Scientific Category :

  Peptides

• Clinical Information :

  Phase 3